Wegener’s granulomatosis

1. High-Yield Summary

Granulomatosis with polyangiitis (GPA), historically designated Wegener’s granulomatosis, is an antineutrophil cytoplasmic antibody (ANCA)-associated necrotizing granulomatous vasculitis predominantly targeting small-to-medium blood vessels of the upper respiratory tract, lower respiratory tract, and kidneys, with prominent musculoskeletal involvement in up to 85% of cases.

• Serologic Benchmark: Cytoplasmic ANCA (c-ANCA) directed against Proteinase 3 (PR3-ANCA) demonstrates 85% to 90% sensitivity in generalized active disease and exceeds 98% specificity; approximately 10% of patients present with perinuclear ANCA (MPO-ANCA) or seronegative disease.
• Musculoskeletal Spectrum: Manifests in 60% to 70% of patients at onset as symmetric or migratory non-erosive oligoarthritis or polyarthralgia (predominantly knees, ankles, and wrists), tenosynovitis, necrotizing myositis, and acute mononeuritis multiplex (foot drop or wrist drop resulting from epineurial vasa nervorum microinfarction).
• Diagnostic Triad: Histopathologic confirmation requires demonstration of the classic triad: necrotizing granulomatous inflammation with geographic basophilic necrosis, small-vessel leukocytoclastic vasculitis, and a pauci-immune pattern lacking significant immune complex or complement deposition.
• Modern Remission Induction: Organ- or life-threatening disease mandates combination induction with high-dose intravenous pulse methylprednisolone and either rituximab (375 mg/m² weekly for 4 weeks or 1000 mg on days 1 and 15) or cyclophosphamide; the oral C5a receptor antagonist avacopan represents an established glucocorticoid-sparing induction adjunct.
• Orthopaedic Surgical Caveats: Elective total joint arthroplasty (most commonly performed for secondary avascular necrosis of the femoral head following high-dose glucocorticoid exposure) is strictly contraindicated during active vasculitis and must be scheduled during verified clinical remission (BVAS = 0) with vigilant perioperative infection prophylaxis and immunosuppressive drug holiday management.

2. Anatomy

The clinical and surgical anatomy of granulomatosis with polyangiitis is defined by the caliber of affected vessels, the specific neurovascular danger zones subjected to ischemic injury, and the specialized tissue planes utilized for diagnostic biopsy and reconstructive interventions.

Vascular Architecture and Ischemic Target Zones:

• Microvascular Caliber: The pathological process selectively damages post-capillary venules, capillaries, arterioles, and small-to-medium muscular arteries ranging from 30 to 100 micrometers in external diameter.
• Vasa Nervorum of Peripheral Nerves: Nutrient epineurial and perineurial arterioles supplying major peripheral nerve trunks lack extensive collateral anastomoses. Transmural necrotizing vasculitis and secondary thrombosis within these vessels cause localized nerve fascicular ischemia and axonal degeneration, manifesting as mononeuritis multiplex. The common fibular (peroneal) nerve at the fibular neck and the tibial nerve in the popliteal fossa and tarsal tunnel are the most frequently compromised lower extremity structures, while the radial and median nerves predominate in the upper extremity.
• Craniomaxillofacial Cartilaginous Framework: The anterior nasal septal cartilage (quadrangular cartilage) relies on mucoperichondrial perfusion from the Kiesselbach plexus (sphenopalatine, anterior ethmoidal, greater palatine, and superior labial arteries). Microvascular occlusion and granulomatous infiltration induce chondrocyte necrosis, cartilaginous septal perforation, and progressive destruction of dorsal nasal structural support, producing the pathognomonic saddle nose deformity.
• Laryngotracheal Airway: The subglottic ring and upper trachea, supplied by branches of the inferior thyroid artery, represent a rigid circumferential structure. Granulomatous mucosal proliferation and secondary fibrous cicatrization at this anatomic junction create circumferential subglottic stenosis.

Neurovascular Danger Zones:

• Orbit and Superior Orbital Fissure: Retro-orbital granulomatous pseudotumors compress the optic nerve (cranial nerve II) within the optic canal and jeopardize cranial nerves III, IV, V1, and VI as they traverse the superior orbital fissure, presenting a critical risk of permanent optic atrophy and ophthalmoplegia.
• Fibular Neck Tunnel: The common fibular nerve courses subcutaneous and taut around the bony neck of the fibula. Ischemic fascicular swelling within this unyielding fibro-osseous tunnel exacerbates compression neuropathy, accelerating irreversible motor loss to the tibialis anterior and extensor hallucis longus.

Surgical Dissection Planes for Diagnostic Tissue Biopsy:

• Sural Nerve and Muscle Biopsy Plane: Access is gained via a longitudinal posterolateral calf incision halfway between the lateral malleolus and the popliteal crease. Dissection proceeds through the superficial subcutaneous fascia to identify the sural nerve immediately adjacent to the lesser saphenous vein. Harvesting a 2 to 3 cm nerve segment with adjacent epineurial soft tissue and superficial muscle fascicles of the lateral gastrocnemius preserves motor function while providing optimal microvascular tissue for histologic evaluation.
• Rigid Transnasal Mucosal Biopsy: Endoscopic instrumentation must harvest tissue from the active hyperemic margins of mucosal ulcerations along the inferior or middle turbinate, avoiding necrotic central eschars which yield only non-diagnostic cellular debris.
• Thoracoscopic Lung Biopsy: Performed via video-assisted thoracoscopic surgery (VATS) using a three-port configuration across the fourth and sixth intercostal spaces to obtain a formal wedge resection of solid or cavitary pulmonary nodules containing viable parenchyma and vascular beds.

3. Pathogenesis

The pathogenesis of granulomatosis with polyangiitis involves an interplay between genetic susceptibility, environmental priming, dysregulated humoral immunity, and aberrant neutrophil-endothelial cell cytotoxicity.

Neutrophil Priming and ANCA Interaction:

• Antigen Translocation: Proinflammatory cytokines, particularly tumor necrosis factor-alpha (TNF-alpha) and interleukin-1beta (IL-1beta), stimulate circulating neutrophils, inducing the translocation of proteinase 3 (PR3)—a 29-kDa neutral serine protease stored within primary azurophilic granules—to the external cell surface membrane.
• Autoantibody Engagement: Circulating IgG autoantibodies against PR3 bind to membrane-bound antigen and concurrently engage neutrophil Fc-gamma receptors (FcγRIIa). This cross-linking activates intracellular tyrosine kinase pathways, culminating in massive neutrophil activation, respiratory burst, and release of reactive oxygen species (ROS).
• Neutrophil Extracellular Traps (NETosis): Activated neutrophils undergo specialized cell death, expelling webs of chromatin coated with PR3, myeloperoxidase, and histones into the microvascular lumen. These NETs inflict direct mechanical and enzymatic damage on vascular endothelial cells, expose neoantigens, and fuel ongoing autoimmune stimulation.

Alternative Complement Pathway Amplification:

Microvascular endothelial injury and neutrophil degranulation cleave complement factor C5, releasing the potent anaphylatoxin C5a. C5a binds to the C5a receptor-1 (C5aR1 / CD88) on neutrophils, creating an intense positive feedback loop that drives further neutrophil recruitment, transmigration through vascular walls, and necrotizing capillaritis.

Histopathologic Hallmarks:

• Geographic Necrosis and Extravascular Granulomas: Large zones of irregularly shaped, basophilic, acellular collagenous necrosis surrounded by a palisade of epithelioid macrophages, lymphocytes, plasma cells, and multinucleated foreign body or Langhans-type giant cells.
• Segmental Necrotizing Vasculitis: Fibrinoid necrosis of the muscular tunica media of arterioles and venules, marked infiltration of the vessel wall with polymorphonuclear leukocytes, leukocytoclasia (nuclear debris), and secondary endoluminal thrombosis.
• Pauci-Immune Immunopathology: Direct immunofluorescence reveals minimal or absent deposition of immunoglobulins (IgG, IgM, IgA) and complement components (C3, C1q) within glomerular and vascular lesions, cleanly differentiating GPA from immune-complex-mediated diseases such as systemic lupus erythematosus and Henoch-Schönlein purpura (IgA vasculitis).

4. Natural History

Prior to the introduction of systemic corticosteroid and cytotoxic therapy in the 1970s, granulomatosis with polyangiitis followed a rapid and uniformly lethal clinical course. Historical natural history cohorts documented a 1-year mortality rate of 82% and a median survival of approximately 5 months from symptom onset. Death was primarily driven by progressive uremia from rapidly progressive crescentic glomerulonephritis (RPGN) or hypoxic respiratory arrest from diffuse alveolar hemorrhage.

Epidemiology:

• Incidence and Prevalence: The annual incidence ranges between 8 and 12 cases per 1,000,000 person-years in North America and Europe, with an estimated prevalence of 30 to 50 cases per 1,000,000 population.
• Demographic Distribution: The disease demonstrates a peak onset between 50 and 70 years of age (median age 55 years). Pediatric and adolescent presentations comprise less than 5% of cases. There is a slight male predilection (male-to-female ratio 1.2:1), and more than 90% of affected individuals are of European descent.

Treated Prognosis and Relapse Dynamics:

With contemporary remission induction regimens (rituximab or cyclophosphamide coupled with glucocorticoids), complete clinical remission is attained in 85% to 93% of patients. Five-year overall survival now exceeds 80% to 85%. However, GPA is characterized by a high propensity for recurrent flares, with 30% to 50% of patients experiencing a disease relapse within 3 to 5 years following initial induction. PR3-ANCA seropositivity, persistent sinonasal colonization with Staphylococcus aureus, lower airway involvement, and premature cessation of maintenance therapy are established risk factors for relapse. Chronic morbidity affects over 80% of long-term survivors, resulting from both permanent vasculitic end-organ destruction (chronic kidney disease, subglottic stenosis, motor deficits from mononeuritis multiplex) and drug-induced complications (osteonecrosis of femoral heads, secondary malignancies, and opportunistic infections).

5. Clinical Presentation

History

Patients typically present with a subacute prodrome of severe constitutional symptoms, including profound fatigue, low-grade fevers, night sweats, anorexia, and involuntary weight loss (>10% of body mass). Organ-specific inquiry reveals:

• Upper Airway and Otorhinolaryngologic Symptoms: Refractory nasal congestion, recurrent bloody rhinorrhea, severe dark adherent nasal crusting, facial pain/pressure over the maxillary sinuses, and conductive hearing loss from serous otitis media. Chronic septal necrosis manifests as collapse of the nasal bridge. Progressive hoarseness, biphasic inspiratory stridor, and exertional shortness of breath signal subglottic tracheal stenosis.
• Lower Airway Symptoms: Persistent dry or productive cough, hemoptysis (ranging from mild blood-streaked sputum to massive pulmonary hemorrhage), and pleuritic chest discomfort.
• Renal Symptoms: Frequently asymptomatic in early stages, but progresses to gross hematuria (tea- or cola-colored urine), foamy urine indicative of proteinuria, oliguria, and peripheral lower extremity edema.
• Musculoskeletal and Neurologic Symptoms: Present in 60% to 70% of patients at initial evaluation. Patients report severe morning stiffness, polyarthralgia, swelling in the knees, ankles, wrists, and metacarpophalangeal joints, and diffuse myalgias. Acute neurologic involvement presents as sudden, asymmetric extremity weakness or numbness, such as an abrupt unilateral foot drop or wrist drop.

Physical Exam

Physical examination requires a systematic multisystem evaluation focusing on upper airway integrity, joint inflammatory signs, peripheral nervous system integrity, and cutaneous markers of vasculitis.

6. Imaging and Diagnostic Studies

A rigorous diagnostic pathway integrates thoracic cross-sectional imaging, maxillofacial computed tomography, serologic immunoassays, urinary sediment microscopy, and confirmatory histopathologic tissue biopsy.

Thoracic Imaging (Chest Radiography & HRCT):

• Pulmonary Nodules and Masses: Multiple, bilateral, randomly distributed pulmonary nodules ranging from several millimeters to 10 centimeters in diameter represent the most common finding. Approximately 40% to 50% of nodules develop central cavitation characterized by thick, irregular walls and air-fluid levels.
• Alveolar Infiltrates and Hemorrhage: Patchy ground-glass opacities, dependent consolidations, and interlobular septal thickening (the “crazy-paving” pattern) reflect active alveolar capillaritis and pulmonary hemorrhage.
• Subglottic and Tracheal Stenosis: High-resolution CT of the neck demonstrates smooth or nodular circumferential narrowing of the subglottic tracheal lumen extending 2 to 4 cm below the true vocal cords, without surrounding extrinsic compression.

Maxillofacial and Sinus Computed Tomography:

Reveals mucosal opacification of the maxillary and ethmoid sinuses, destruction of the cartilaginous and bony nasal septum, and erosion of the medial maxillary sinus walls. Longstanding disease produces prominent bony sclerosis and hyperostosis (neo-osteogenesis) of the sinus margins.

Musculoskeletal Imaging:

• Conventional Radiographs: Reveal soft-tissue swelling and periarticular osteopenia. Unlike rheumatoid arthritis, progressive marginal bony erosions and joint space destruction are characteristically absent, confirming a non-erosive arthropathy.
• Magnetic Resonance Imaging (MRI): Essential for evaluating suspected mononeuritis multiplex (demonstrating nerve fascicular hyperintensity and contrast enhancement on T1 post-contrast sequences), active inflammatory myositis (hyperintense muscle edema on STIR/T2-weighted images), and avascular necrosis (AVN) of the femoral head in patients on systemic corticosteroids (pathognomonic subchondral “double-line sign” on T2-weighted sequences).

Serologic, Laboratory, and Urine Evaluation:

• ANCA Testing (Gold Standard Serology): Indirect immunofluorescence (IIF) demonstrates a cytoplasmic (c-ANCA) staining pattern with diffuse granular fluorescence throughout neutrophil cytoplasm. Antigen-specific enzyme-linked immunosorbent assay (ELISA) or chemiluminescence immunoassay (CLIA) confirms autoantibodies directed against proteinase 3 (PR3-ANCA). Overall sensitivity is 90% in generalized disease (60% to 70% in localized respiratory forms) with specificity exceeding 98%. Perinuclear ANCA (MPO-ANCA) is identified in 10% to 15% of atypical variants.
• Inflammatory Markers: Markedly elevated erythrocyte sedimentation rate (ESR > 80 mm/hr) and C-reactive protein (CRP > 50 mg/L) correlate with systemic disease activity.
• Active Urinary Sediment: Microscopic examination demonstrating dysmorphic red blood cells (>10/HPF), acanthocytes, and red blood cell casts is pathognomonic for active glomerulonephritis, accompanied by sub-nephrotic proteinuria (>0.5 g/24 hr).

Histopathologic Confirmation:

• Renal Biopsy: Demonstrates focal segmental necrotizing crescentic glomerulonephritis with a pauci-immune immunofluorescence profile (scant or absent IgG and C3 staining).
• VATS Surgical Lung Biopsy: Provides the highest diagnostic yield (80% to 90%) for the complete histopathologic triad: parenchymal geographic necrosis, granulomatous inflammation with giant cells, and transmural necrotizing vasculitis.
• Sural Nerve / Muscle Biopsy: Demonstrates necrotizing arteritis of small epineurial and perimysial arteries, confirming the vascular etiology of mononeuritis multiplex.

7. Classification

Modern clinical classification relies on the validated 2022 American College of Rheumatology / European Alliance of Associations for Rheumatology (ACR/EULAR) classification criteria and the EUVAS / EULAR disease severity stratification.

2022 ACR/EULAR Classification Criteria for Granulomatosis with Polyangiitis

These criteria apply to patients presenting with a documented diagnosis of small- or medium-vessel vasculitis once mimics have been excluded. A cumulative score of 5 or greater classifies the patient as having Granulomatosis with Polyangiitis with 93% sensitivity and 94% specificity.

EUVAS / EULAR Disease Severity Stratification

Therapeutic algorithms are dictated by the European Vasculitis Study Group (EUVAS) severity classification, categorizing patients based on threatened organ function and immediate risk of mortality.

8. Treatment

Medical Therapy

Medical management is divided into acute remission induction and prolonged remission maintenance, tailored to disease severity.

1. Remission Induction (Organ- or Life-Threatening Disease):

• Systemic Glucocorticoids: Intravenous methylprednisolone pulses (500 to 1000 mg daily for 3 consecutive days), followed by oral prednisone (1 mg/kg/day, maximum 80 mg/day). Tapering follows the PEXIVAS reduced-dose glucocorticoid protocol, which aims to reach 5 to 7.5 mg daily by month 6, achieving equivalent disease control with a 40% reduction in severe infectious mortality compared to traditional high-dose regimens.
• Targeted Biologic Induction (Rituximab): Administered as 375 mg/m² intravenously once weekly for 4 weeks, or 1000 mg intravenously on days 1 and 15. The landmark RAVE trial established rituximab as non-inferior to daily cyclophosphamide for initial induction and superior for patients presenting with relapsing disease. Rituximab is the preferred first-line agent, especially in young patients seeking fertility preservation.
• Alkylating Induction (Cyclophosphamide): Intravenous pulsed cyclophosphamide (15 mg/kg every 2 to 3 weeks for 3 to 6 months, adjusted downward for age >60 and reduced eGFR) with mandatory mesna uroprotection, or oral cyclophosphamide (2 mg/kg/day). Cyclophosphamide remains an alternative for patients with severe glomerulonephritis or contraindications to rituximab.
• Targeted Complement Inhibition (Avacopan): An oral selective C5a receptor-1 (C5aR1) antagonist administered at 30 mg twice daily with food. Supported by the ADVOCATE trial, avacopan significantly reduces cumulative glucocorticoid exposure and improves sustained remission and eGFR recovery at 52 weeks.

2. Remission Induction (Non-Organ-Threatening / Localized Disease):

Oral methotrexate (20 to 25 mg once weekly with folic acid supplementation) or mycophenolate mofetil (2 to 3 g daily) combined with a rapid glucocorticoid taper represents standard therapy for patients lacking renal, alveolar, or critical neurologic involvement.

3. Remission Maintenance Therapy:

• Scheduled Rituximab: 500 mg intravenously every 6 months for a minimum of 24 to 36 months following induction. The MAINRITSAN trial demonstrated that scheduled rituximab maintenance is substantially superior to oral azathioprine in preventing major disease relapses (5% vs. 29% relapse rate at 28 months).
• Alternative Oral Maintenance: Oral azathioprine (2 mg/kg/day) or methotrexate (20 to 25 mg/week) serves as second-line maintenance for patients intolerant or unable to access rituximab.

4. Mandatory Infection Prophylaxis:

Trimethoprim-sulfamethoxazole (TMP-SMX, 800/160 mg three times weekly or 400/80 mg daily) is mandatory for all patients undergoing induction and immunosuppressive maintenance to prevent life-threatening Pneumocystis jirovecii pneumonia (PJP). Secondary benefit includes suppression of nasal Staphylococcus aureus carriage, a known trigger for upper airway relapses. In sulfa-allergic patients, dapsone (100 mg daily) or atovaquone (1500 mg daily) must be substituted after confirming normal G6PD activity.

Nonoperative and Supportive Care

• Sinonasal Care: High-volume isotonic or hypertonic sterile saline nasal irrigations (twice daily), intranasal mupirocin ointment application to active crusted lesions, and room humidification to preserve mucosal hydration and prevent crust impaction.
• Neuromuscular and Orthotic Rehabilitation: Patients with common fibular nerve mononeuritis multiplex require immediate fitting with a custom lightweight polypropylene or carbon-fiber ankle-foot orthosis (AFO) to eliminate foot drop, prevent steppage gait tripping, and avert secondary ankle inversion sprains. Physical therapy implements passive stretching to prevent Achilles tendon contracture, accompanied by progressive isometric and proprioceptive strengthening.
• Bone Health Protection: Baseline dual-energy X-ray absorptiometry (DEXA) scanning is mandatory at diagnosis. All patients receiving prolonged systemic glucocorticoids must initiate daily calcium (1200 mg) and vitamin D3 (1000 to 2000 IU), coupled with an oral bisphosphonate (alendronate 70 mg weekly) or intravenous zoledronic acid (5 mg annually) to prevent rapid bone mineral density loss and avascular necrosis.

Operative Treatment and Orthopaedic Considerations

Surgical intervention in patients with GPA falls into three broad categories: diagnostic biopsies, airway/craniofacial reconstructions, and elective orthopaedic reconstructive procedures.

• Subglottic Stenosis Endoscopic Interventions: Circumferential subglottic stenosis is managed primarily via rigid bronchoscopic balloon dilatation combined with radial mucosal micro-incisions and intralesional corticosteroid injection (triamcinolone acetonide 40 mg/mL). Laser ablation and open cricotracheal resection are reserved for dense, mature fibrous stenosis refractory to medical and endoscopic therapy. Tracheostomy is strictly avoided unless required as an emergent life-saving bridge to definitive airway stabilization.
• Craniofacial Reconstruction (Saddle Nose Correction): Structural reconstruction of the nasal dorsum utilizing autologous costal cartilage, auricular cartilage, or calvarial bone grafts must be deferred until the patient has maintained complete clinical and serologic remission for a minimum of 12 to 24 months. Operating during active or subclinical inflammation results in rapid graft resorption, mucocutaneous necrosis, and reconstructive failure.
• Secondary Avascular Necrosis (AVN) and Arthroplasty Management: Glucocorticoid pulse and maintenance therapy causes symptomatic osteonecrosis of the femoral head in 10% to 15% of GPA patients, frequently presenting bilaterally. Pre-collapse disease (Ficat & Arlet Stage I/II) can be managed with core decompression. Once subchondral crescent collapse occurs (Stage III/IV), total hip arthroplasty (THA) is the definitive surgical solution.

Perioperative Protocols for Elective Orthopaedic Surgery:

• Remission Requirement: Elective joint reconstruction must strictly proceed only during quiescent disease (Birmingham Vasculitis Activity Score [BVAS] = 0) with normal acute-phase reactants.
• Immunosuppressive Drug Windows: Elective arthroplasty should be timed at the end of the rituximab dosing cycle, ideally 5 to 6 months following the previous infusion, and 2 to 4 weeks prior to the next scheduled maintenance dose, allowing early peripheral B-cell reconstitution. Methotrexate may be continued if renal function is stable, whereas mycophenolate mofetil and azathioprine should be held 1 week prior to surgery and resumed 10 to 14 days postoperatively after primary wound healing is verified.
• Stress-Dose Glucocorticoids: Patients who have received greater than 5 mg of prednisone equivalent daily for more than 3 weeks within the preceding 12 months have suppressed hypothalamic-pituitary-adrenal axis function. Perioperative IV hydrocortisone (50 to 100 mg administered immediately prior to induction, followed by 50 mg every 8 hours for 24 hours) prevents acute intraoperative hemodynamic collapse from secondary adrenal insufficiency.
• Infection Surveillance and Wound Closure: GPA patients carry a 2- to 3-fold higher risk of superficial wound breakdown, delayed healing, and deep periprosthetic joint infection (PJI) secondary to microvascular fragility, chronic nasal S. aureus colonization, and immunosuppression. Mupirocin nasal decolonization, weight-based cefazolin prophylaxis, meticulous layered closure, and prolonged suture retention (14 to 21 days) are mandatory.

Indications and Contraindications

• Emergent Systemic Induction: Indicated by active glomerulonephritis (dysmorphic hematuria, proteinuria >0.5 g/24h, or serum creatinine elevation >30%), acute hemoptysis or pulmonary infiltrates, or sudden mononeuritis multiplex (acute foot/wrist drop).
• Endoscopic Airway Dilatation: Indicated for symptomatic subglottic stenosis with luminal diameter reduction to less than 6 mm or peak expiratory flow rate declining below 50% of predicted.
• Total Joint Arthroplasty: Indicated for severe mechanical pain and structural joint collapse (Ficat Stage III/IV osteonecrosis) failing 6 months of nonoperative management.
• Absolute Contraindications to Elective Surgery: Active systemic vasculitis flare (BVAS > 0), active glomerulonephritis, severe neutropenia (absolute neutrophil count < 1,000/microL), or active opportunistic systemic infection.

9. Outcome

Modern clinical outcomes in granulomatosis with polyangiitis reflect a balance between successful disease control and the burden of cumulative therapy-related morbidity.

Remission and Survival Statistics:

• Remission Rates: First-line induction with rituximab or cyclophosphamide induces complete clinical remission in 85% to 93% of patients by 6 months.
• Overall Survivorship: Five-year survival rates are 82% to 88%, and ten-year survival ranges between 75% and 80%. Primary causes of early mortality (within 1 year) are severe infections (accounting for 50% of deaths) and active vasculitis, whereas late mortality is driven by cardiovascular disease, end-stage renal disease, and secondary malignancies.
• Relapse Incidence: Cumulative 5-year relapse rates remain substantial at 35% to 50%, underscoring the necessity of scheduled maintenance therapy.

Functional Outcomes and Patient-Reported Measures (PROMs):

• Physical Function (SF-36 and PROMIS): Physical Component Summary (PCS) scores improve significantly following remission induction but plateau 1 to 1.5 standard deviations below age-matched healthy population norms, driven by chronic fatigue, diffuse arthralgias, and peripheral neuropathic deficits.
• Neuromuscular Deficit Resolution: Motor recovery following vasculitic mononeuritis multiplex is slow and often incomplete. Approximately 45% to 50% of patients achieve functional recovery of ankle dorsiflexion within 12 to 18 months, whereas 25% to 30% suffer permanent deep fibular nerve paralysis requiring permanent orthotic brace dependence.
• Arthroplasty Survivorship: Total hip and knee arthroplasties performed for secondary corticosteroid osteonecrosis achieve significant improvements in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) and Hip Disability and Osteoarthritis Outcome Score (HOOS) scores, with 10-year implant survivorship exceeding 90%. However, vasculitis patients demonstrate an increased relative risk of periprosthetic joint infection (HR 2.1 to 2.5) compared to primary osteoarthritis cohorts.

10. Complications

Complications in GPA are categorized into direct vasculitic organ destruction and iatrogenic sequelae resulting from prolonged immunosuppression.

11. Pearls and Pitfalls

• Pearl — The Refractory Sinusitis Red Flag: Any adult patient presenting with persistent, destructive rhinosinusitis, bloody nasal discharge, or new-onset conductive hearing loss who has failed multiple empiric outpatient antibiotic courses must be evaluated for GPA with immediate c-ANCA/anti-PR3 serology and microscopic urinalysis.
• Pearl — Acute Foot Drop in Vasculitis: An abrupt unilateral foot drop in a patient with constitutional or respiratory symptoms is ischemic mononeuritis multiplex resulting from epineurial vasa nervorum necrotizing vasculitis, not simple lumbar disc radiculopathy. It mandates urgent escalation of systemic immunosuppression to salvage peripheral nerve viability.
• Pearl — Mandatory PJP Prophylaxis: Never initiate induction therapy with cyclophosphamide or rituximab without simultaneously prescribing trimethoprim-sulfamethoxazole or dapsone; opportunistic Pneumocystis pneumonia represents the single most preventable cause of early induction mortality.
• Pitfall — Cosmetic Rhinoplasty During Active Disease: Performing structural septal or nasal reconstructive surgery during active or subclinically active disease guarantees graft resorption, mucosal ulceration, infection, and severe cosmetic failure. Reconstructive surgery must be deferred until verified clinical and serological remission has persisted for at least 12 to 24 months.
• Pitfall — Misinterpreting Osteonecrosis as Vasculitic Arthralgia: New-onset groin or knee pain in a patient receiving high-dose glucocorticoids must never be assumed to be a vasculitic flare. Immediate pelvic MRI must be performed to detect early pre-collapse avascular necrosis of the femoral head.
• Pitfall — Treating the ANCA Titer Rather Than the Patient: An isolated rise in PR3-ANCA titer in an asymptomatic patient with stable renal parameters and an inactive urine sediment (BVAS = 0) does not justify restarting toxic induction chemotherapy. Treatment decisions must be driven by objective clinical evidence of end-organ inflammation.

12. Controversy

Modern management of granulomatosis with polyangiitis encompasses several ongoing therapeutic and diagnostic debates:

• Optimal Duration of Maintenance Therapy: While the MAINRITSAN trial protocol established scheduled rituximab for 18 to 24 months as the standard of care, up to 40% of patients experience a clinical flare following drug discontinuation. The international rheumatology community is divided between fixed 2-year cessation, extending maintenance to 5 years, or continuing indefinite low-dose maintenance in high-risk patients (PR3-ANCA seropositive, persistent upper airway disease, or history of multiple relapses).
• Role of Therapeutic Plasma Exchange (PEX): The landmark PEXIVAS randomized controlled trial evaluated 704 patients with severe ANCA-associated vasculitis and demonstrated that routine plasma exchange did not reduce death or end-stage kidney disease. However, controversy persists regarding whether a narrow subpopulation of patients presenting with catastrophic diffuse alveolar hemorrhage and profound arterial hypoxemia still derive a life-saving oxygenation benefit from acute rescue plasmapheresis.
• Targeted Complement Inhibition vs. Standard Glucocorticoids: The approval of avacopan (oral C5aR1 antagonist) based on the ADVOCATE trial demonstrated superiority in sustained remission and renal recovery with significant reduction in glucocorticoid toxicity. Ongoing debate centers on whether avacopan can completely replace systemic glucocorticoids in all induction candidates or should be selectively reserved as a steroid-sparing adjunct in high-risk diabetic, osteoporotic, or elderly patients.
• Biomarker-Guided vs. Fixed-Interval Retreatment: Debate continues whether maintenance rituximab should be administered on a strict fixed calendar schedule (500 mg every 6 months) or tailored dynamically based on serial monitoring of peripheral blood CD19+ B-cell repopulation and rising PR3-ANCA titers.

13. Evidence-Based Synthesis

Modern clinical decision-making is grounded in high-quality randomized controlled trials and prospective registry analyses, corroborated by seminal biomechanical and anatomical descriptions.

14. References

• Hellmich B, Sanchez-Alamo B, Schirmer JH et al. EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update. Ann Rheum Dis. 2024. doi:10.1136/ard-2022-223764 [Level I: Evidence-Based Clinical Practice Guideline / Systematic Review]
• Stone JH, Merkel PA, Spiera R et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 2010. doi:10.1056/NEJMoa0909905 [Level I: Double-Blind Randomized Controlled Non-Inferiority Trial]
• Walsh M, Merkel PA, Peh CA et al. Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis. N Engl J Med. 2020. doi:10.1056/NEJMoa1803537 [Level I: Multicenter 2×2 Factorial Randomized Controlled Trial]
• Robson JC, Grayson PC, Ponte C et al. 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for granulomatosis with polyangiitis. Ann Rheum Dis. 2022. doi:10.1136/annrheumdis-2021-221795 [Level II: Prospective Multicenter Diagnostic Validation Study]
• Jennette JC, Falk RJ, Bacon PA et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 2013. doi:10.1002/art.37715 [Level V: International Consensus Statement & Nomenclature System]

15. Master Class Pro-Tip

When an orthopaedic surgeon evaluates a patient with suspected systemic vasculitis or unexplained destructive sinonasal and musculoskeletal symptoms, diagnostic discipline dictates three immutable clinical rules: First, never initiate systemic corticosteroid pulses prior to obtaining an active urine sediment, chest imaging, and serology, as even 48 hours of high-dose steroids can suppress cellular infiltration and render tissue biopsies inconclusive. Second, treat an acute foot drop in this clinical context as an emergent microvascular ischemic event (mononeuritis multiplex); immediate multi-agent immunosuppression combined with neutral-position orthotic bracing is the sole mechanism to rescue axonal fascicles before irreversible Wallerian degeneration ensues. Third, in patients with established disease requiring elective joint replacement for steroid-induced avascular necrosis, strict perioperative coordination is paramount: verify complete quiescent remission (BVAS = 0), schedule surgery at the 5- to 6-month trough of the rituximab cycle, administer stress-dose perioperative hydrocortisone to prevent adrenal crisis, and retain surgical sutures for a full 21 days to prevent catastrophic wound breakdown.

Master Class Surgical Pearl: Musculoskeletal Vigilance in Systemic Vasculitis